Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute
Screening of healthy subjects is now underway
Phase 1-2a study to provide valuable insights into the safety and activity of avenanthramides in managing conditions related to inflammation
Related news for (CRPOF)
- Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company